0 903

Cited 3 times in

Fibrosis-matched outcomes between chronic hepatitis B patients with drug-induced virological response and inactive carriers

DC Field Value Language
dc.contributor.author김도영-
dc.contributor.author김범경-
dc.contributor.author김승업-
dc.contributor.author박준용-
dc.contributor.author안상훈-
dc.contributor.author이혜원-
dc.contributor.author한광협-
dc.date.accessioned2019-03-15T02:25:50Z-
dc.date.available2019-03-15T02:25:50Z-
dc.date.issued2019-
dc.identifier.issn1478-3223-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/167474-
dc.description.abstractBACKGROUND & AIMS: We compared the risk of hepatocellular carcinoma (HCC) development between patients with chronic hepatitis B (CHB) who achieved virological response (VR; HBV-DNA < 2000 IU/mL) with nucleos(t)ide analogues (NUCs) treatment (NUC-VR group) and patients with inactive CHB phase (ICHBP group). METHODS: To adjust for imbalances between NUC-VR and ICHBP groups, propensity score matching (PSM) models with 1:1 ratios were performed. RESULTS: This study included 2032 patients (n = 1291 in NUC-VR group and n = 741 in ICHBP group). Before PSM, NUC-VR group was at higher risk of HCC development than ICHBP group at 7 years (9.4% in NUC-VR group vs 3.3% in ICHBP group; P < 0.001). However, after PSM, the cumulative HCC development rates at 7 years were similar in NUC-VR and ICHBP groups using the three PSM models [2.0% vs 4.3%, PSM model-1 (612 pairs); 3.7% vs 4.4%, PSM model-2 (618 pairs); and 2.4% vs 4.3%, PSM model-3 (610 pairs)] (all P > 0.05). CONCLUSIONS: After adjusting heavier hepatic fibrosis burden in NUC-VR group, overall clinical outcomes between 2 groups had become comparable. Therefore, if appropriate, NUCs to prevent viral replication and hepatic inflammation are required for achieving better prognosis.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherWiley-Blackwell-
dc.relation.isPartOfLIVER INTERNATIONAL-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleFibrosis-matched outcomes between chronic hepatitis B patients with drug-induced virological response and inactive carriers-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorHye Soo Kim-
dc.contributor.googleauthorOidov Baatarkhuu-
dc.contributor.googleauthorHye Won Lee-
dc.contributor.googleauthorJun Yong Park-
dc.contributor.googleauthorDo Young Kim-
dc.contributor.googleauthorSang Hoon Ahn-
dc.contributor.googleauthorKijun Song-
dc.contributor.googleauthorKwang‐Hyub Han-
dc.contributor.googleauthorBeom Kyung Kim-
dc.contributor.googleauthorSeung Up Kim-
dc.identifier.doi10.1111/liv.13948-
dc.contributor.localIdA00385-
dc.contributor.localIdA00487-
dc.contributor.localIdA00654-
dc.contributor.localIdA01675-
dc.contributor.localIdA02226-
dc.contributor.localIdA03318-
dc.contributor.localIdA04268-
dc.relation.journalcodeJ02171-
dc.identifier.eissn1478-3231-
dc.identifier.pmid30280461-
dc.identifier.urlhttps://onlinelibrary.wiley.com/doi/full/10.1111/liv.13948-
dc.subject.keywordfibrosis-
dc.subject.keywordhepatitis B-
dc.subject.keywordhepatocellular carcinoma-
dc.subject.keywordmatching-
dc.subject.keywordprognosis-
dc.contributor.alternativeNameKim, Do Young-
dc.contributor.affiliatedAuthor김도영-
dc.contributor.affiliatedAuthor김범경-
dc.contributor.affiliatedAuthor김승업-
dc.contributor.affiliatedAuthor박준용-
dc.contributor.affiliatedAuthor안상훈-
dc.contributor.affiliatedAuthor이혜원-
dc.contributor.affiliatedAuthor한광협-
dc.citation.volume39-
dc.citation.number1-
dc.citation.startPage81-
dc.citation.endPage89-
dc.identifier.bibliographicCitationLIVER INTERNATIONAL, Vol.39(1) : 81-89, 2019-
dc.identifier.rimsid39813-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.